XE:BAYN – The News Desk

Bayer CEO Says Breakup Wouldn’t Fix All of the Company’s Ills

25Nov

By adminNo Comments

World

Bayer CEO Says Breakup Wouldn’t Fix All of the Company’s Ills

BERLIN—Bayer Chief Executive Bill Anderson said the company would bounce back quickly from a recent spate of bad news, and warned that a breakup of the pharmaceutical and agricultural company was no universal cure for its ailments.A stream of negative news has rekindled calls from investors for Bayer to unlock value by spinning off its units into separate businesses. But in an interview with The Wall Street Journal this week, Anderson said the company couldn’t be distracted from the tough restructuring to fix the businesses.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case

20Nov

By adminNo Comments

World

Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case

Updated Nov. 20, 2023 3:16 pm ETBayer shares fell sharply after the company stopped a late-stage study for a blood-thinning drug early because of lack of efficacy and was told to pay $1.56 billion in a lawsuit relating to its Roundup weedkiller.Bayer said late Sunday that it discontinued a Phase 3 clinical trial to test its experimental drug asundexian for prevention of stroke and systemic embolism for patients with the heart-rhythm disorder atrial fibrillation.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Bayer Told to Pay $1.56 Billion After Losing Roundup Case

18Nov

By adminNo Comments

World

Bayer Told to Pay $1.56 Billion After Losing Roundup Case

Bayer faces a payout of $1.56 billion after a Missouri jury found in favor of three people who blamed its popular Roundup weedkiller for causing their cancers.The ruling is the fourth in a row to go against Bayer during a roller-coaster five-year legal battle over Roundup, the world’s most popular weedkiller, that included nine straight victories for the company, as well as earlier losses. The cases represent tens of thousands of claims from farmers and gardeners.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Bayer Pulling Lymphoma Drug Aliqopa From U.S.

13Nov

By adminNo Comments

World

Bayer Pulling Lymphoma Drug Aliqopa From U.S.

Nov. 13, 2023 10:35 am ETGerman drugs-to-crops giant Bayer is pulling Aliqopa from the U.S. after a confirmatory trial of the lymphoma drug missed its primary endpoint.Bayer on Monday said it will work with the U.S. Food and Drug Administration on a voluntary withdrawal of Aliqopa, which won accelerated approval from the agency in 2017 for adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

8Nov

By adminNo Comments

World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0833 GMT – Bayer posted third-quarter results below forecasts but backed its guidance for the year in what Deutsche Bank analysts call a positive surprise. “The results were more or less expected, and the market should take the guidance confirmation positively, as there was a concern that Bayer might have to cut it again,” the analysts say in a note to clients. The German pharmaceutical and agricultural conglomerate has been grappling with lower prices for glyphosate, the active ingredient found in herbicides and other weed-control products, a development that in July forced the group to slash its overall sales and earnings guidance for the year. Bayer sh...

Bayer Weighs Structural Changes But Rules Out Three-Way Split

8Nov

By adminNo Comments

World

Bayer Weighs Structural Changes But Rules Out Three-Way Split

Updated Nov. 8, 2023 3:15 am ETBayer Chief Executive Bill Anderson said he is looking at options to overhaul the company’s structure and remove multiple layers of management in a move that will result in significant job cuts, but ruled out splitting the group into three businesses.Anderson, who took the helm of the German pharmaceutical and agricultural conglomerate from Werner Baumann in June, said he had engaged a team of advisors to look at various structural options, including the separation of either its crop science or consumer health divisions.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Intrepid Investors Look for Bargains in Ukraine—Bomb Shelter Required

23Oct

By adminNo Comments

World

Intrepid Investors Look for Bargains in Ukraine—Bomb Shelter Required

Updated Oct. 23, 2023 12:02 am ETListen to article(2 minutes)John Mazarakis got rich lending money to cannabis companies and running a chain of pizzerias along the Eastern Seaboard. His next big bet: houses and industrial parks in war-torn Ukraine.Mazarakis and the $2 billion asset manager he co-founded, Chicago Atlantic, are preparing to invest as much as $250 million in the country. He isn’t alone. Steel-nerved investors are trickling back into Ukraine, lured by the chance to help the country in its fight against Russia—and to score assets on the cheap.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8